As we roll into the new year, the outlook seems a bit shaky. Can we expect sunnier days ahead? In the biopharma world, it’s time to step up. Companies will need to impress if they want to attract investor cash. To give you a better feel for upcoming developments, our 2024 Preview infographic breaks down […]
Share:
As we roll into the new year, the outlook seems a bit shaky. Can we expect sunnier days ahead? In the biopharma world, it’s time to step up. Companies will need to impress if they want to attract investor cash.
To give you a better feel for upcoming developments, our 2024 Preview infographic breaks down the key trends.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
